On (b)(6) 2020 a patient underwent a bilateral common iliac stenting, in the common iliac artery.Using an 8 fr 10 cm terumo sheath, the physician advanced a gore® viabahn® vbx balloon expandable endoprosthesis (vbx) through the common femoral artery.It was reported the artery had calcium present and the physician believes it caused the device to slip off the balloon in the femoral artery.A vascular surgeon assisted in the procedure and performed a cut down of the common femoral artery to remove the un-deployed vbx device.They proceeded to use a new vbx device of the same size and completed the procedure successfully.The patient tolerated the procedure and is doing fine.
|
The device was identified to be 8 x 59 mm configuration based of the physical evaluation.The device was returned without a delivery system.Engineering evaluation conclusion(s) are: device profile is 100% verified during the vbx manufacturing process.The device history file was reviewed and no anomalies were identified.Crush force is controlled through machine maintenance and calibration.Machine history files were reviewed and no non-routine maintenance was identified.Based on the device evaluation performed, no manufacturing anomalies were identified to which the event could be definitively attributed.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any "defects" or has "malfunctioned".These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|